Explore the Journal of Drugs in Dermatology (JDD), a monthly peer-reviewed, PubMed® indexed dermatology journal & online resource.
Complimentary subscriptions for US dermatologists, dermatology residents, nurse practitioners and physician assistants.
Lilly published the results of a Phase 3b clinical trial that showed treatment with concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) was superior to ixekizumab alone in patients with active psoriatic…
In this article from JDD: Excimer laser delivers measurable PASI gains but evidence is limited A JDD meta‑analysis of 308 nm excimer laser treatment for plaque psoriasis pooled four clinical…
A JDD retrospective review links generalized disease to higher comorbidity burden and reports favorable response to pentoxifylline In this article from JDD’s February 2026’s issue, authors present a single center,…
Curated by the JDD Editors Missed any of our February highlights? February is packed with intriguing articles, and you’ll want to start to dive in! Catch up with this curated…
Behind the Bottle Part Deux: A Scientific, Socratic Squawk on Sensitive and Susceptible Skin Guest: Dr. Peter Lio The JDD Podcast returns with Part 2 of “Behind the Bottle”, hosted…
From the Vault: A JDD survey of dermatology residents highlights concerns among underrepresented groups that may influence interest in Mohs micrographic surgery and dermatologic oncology fellowships In this article from…